ATE469161T1 - Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung - Google Patents

Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung

Info

Publication number
ATE469161T1
ATE469161T1 AT03784564T AT03784564T ATE469161T1 AT E469161 T1 ATE469161 T1 AT E469161T1 AT 03784564 T AT03784564 T AT 03784564T AT 03784564 T AT03784564 T AT 03784564T AT E469161 T1 ATE469161 T1 AT E469161T1
Authority
AT
Austria
Prior art keywords
optionally substituted
group etc
alkyl group
chem
production
Prior art date
Application number
AT03784564T
Other languages
English (en)
Inventor
Hirotaka Teranishi
Nobuhiko Fushimi
Shigeru Yonekubo
Kazuo Shimizu
Toshihide Shibazaki
Masayuki Isaji
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Application granted granted Critical
Publication of ATE469161T1 publication Critical patent/ATE469161T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03784564T 2002-08-08 2003-08-07 Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung ATE469161T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002232074 2002-08-08
JP2002321729 2002-11-05
PCT/JP2003/010048 WO2004014932A1 (ja) 2002-08-08 2003-08-07 ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体

Publications (1)

Publication Number Publication Date
ATE469161T1 true ATE469161T1 (de) 2010-06-15

Family

ID=31719857

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784564T ATE469161T1 (de) 2002-08-08 2003-08-07 Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung

Country Status (19)

Country Link
US (2) US7375087B2 (de)
EP (1) EP1544208B1 (de)
JP (1) JP4540475B2 (de)
KR (1) KR100985502B1 (de)
AT (1) ATE469161T1 (de)
AU (1) AU2003254847B2 (de)
BR (1) BRPI0313290B1 (de)
CA (1) CA2494179C (de)
DE (1) DE60332743D1 (de)
ES (1) ES2345250T3 (de)
HK (1) HK1082743A1 (de)
IL (1) IL166748A0 (de)
MX (1) MXPA05001549A (de)
NO (1) NO330456B1 (de)
NZ (1) NZ538117A (de)
PL (1) PL213095B1 (de)
RU (1) RU2356906C2 (de)
TW (1) TW200413401A (de)
WO (1) WO2004014932A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025598A1 (en) 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
MXPA05001549A (es) * 2002-08-08 2005-05-05 Kissei Pharmaceutical Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion.
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
AU2003262262A1 (en) * 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
JPWO2004050122A1 (ja) * 2002-12-04 2006-03-30 キッセイ薬品工業株式会社 高血糖症に起因する疾患の予防又は治療剤
AU2003289440A1 (en) * 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
JP5086643B2 (ja) * 2004-11-18 2012-11-28 キッセイ薬品工業株式会社 1−置換−3−(β−D−グリコピラノシル)含窒素ヘテロ環化合物、及びそれを含有する医薬
FR2878523B1 (fr) * 2004-11-30 2007-09-14 Oreal Nouveaux derives sulfamides et leur utilisation cosmetique
US7887824B2 (en) 2004-11-30 2011-02-15 L'oreal Sulfamide derivatives and cosmetic use thereof
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AU2006271653A1 (en) * 2005-07-22 2007-01-25 Boehringer Ingelheim International Gmbh Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
JP2009167103A (ja) * 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd ピラゾリル5−チオグリコシド化合物
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2076503B1 (de) 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenylglycitolverbindung zur behandlung von diabetes
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
CA2655937A1 (en) 2006-06-29 2008-01-03 Taisho Pharmaceutical Co., Ltd. C-phenyl 1-thioglucitol compound
WO2008072726A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-フェニル 1-チオ-d-グルシト-ル誘導体
KR101506935B1 (ko) * 2007-04-02 2015-03-31 테라코스, 인코포레이티드 벤질릭 글리코시드 유도체 및 사용 방법
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
AR068016A1 (es) 2007-08-23 2009-10-28 Theracos Inc Derivados de bencilbenceno, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por sglt
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
KR101416561B1 (ko) * 2007-12-27 2014-07-08 깃세이 야쿠힌 고교 가부시키가이샤 피라졸 유도체의 모노세박산염
RU2530494C2 (ru) 2008-08-22 2014-10-10 Теракос, Инк. Способ получения ингибиторов sglt2
PT2334687E (pt) * 2008-08-28 2012-04-13 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
SI2395983T1 (sl) 2009-02-13 2020-08-31 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, ki obsega SGLT2 inhibitor, DPP-IV inhibitor in po izbiri nadaljnje antidiabetično sredstvo in uporabe le-teh
CN102414191B (zh) 2009-02-23 2014-04-16 大正制药株式会社 4-异丙苯基山梨醇化合物作为sglt1抑制剂
EP2298782A1 (de) * 2009-08-26 2011-03-23 Sanofi-Aventis Verfahren zur Herstellung von Pyrazol-glykosid-Derivate
US8147801B2 (en) 2009-09-15 2012-04-03 Janssen Pharmaceutica, N.V. Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion
ES2546762T3 (es) 2009-09-30 2015-09-28 Boehringer Ingelheim International Gmbh Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo
JP5736377B2 (ja) * 2009-09-30 2015-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)ベンジル]ベンゼンの結晶形の調製方法
AU2010302642A1 (en) * 2009-10-02 2012-04-26 Sanofi Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
RS53827B1 (en) 2009-11-02 2015-06-30 Pfizer Inc. DIOKSA-BICYCLE DERIVATIVES [3.2.1] OCTOBER-2,3,4-TRIOLA
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
BR112013000626B1 (pt) 2010-07-09 2019-11-26 Bhv Pharma Inc formulação farmacêutica e método para preparar uma forma de dosagem da mesma
JP2013224263A (ja) * 2010-08-19 2013-10-31 Taisho Pharmaceutical Co Ltd 4−イソプロピルフェニルグルシトール化合物
EP2607360B1 (de) 2010-08-20 2015-08-19 Taisho Pharmaceutical Co., Ltd. 4-Isopropyl-6-Methoxyphenyl-Glucitol-Verbindung
US8822674B2 (en) 2010-08-20 2014-09-02 Taisho Pharmaceutical Co., Ltd Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2012176804A1 (ja) * 2011-06-20 2012-12-27 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体
AU2012280508A1 (en) 2011-07-01 2013-12-12 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) * 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
RU2648467C2 (ru) 2013-02-04 2018-03-26 Тайсо Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое лекарственное средство для лечения запора
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1083335A (en) * 1976-05-10 1980-08-12 Chemed Corporation Composition and method of inhibiting corrosion
US5274111A (en) * 1992-04-07 1993-12-28 American Home Products Corporation Trifluoromethyl substituted 1H-pyrazoles and derivatives thereof
CA2300211A1 (en) 1997-08-27 1999-03-04 Masato Iwasaki Sustained-release oral preparation
JP2001523704A (ja) 1997-11-25 2001-11-27 バイエル・アクチエンゲゼルシヤフト α−グルコシダーゼ阻害剤を含んで成る持続放出性製剤
NZ514661A (en) * 1999-04-06 2003-06-30 Sankyo Co alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions
JP2001002567A (ja) 1999-04-20 2001-01-09 Takeda Chem Ind Ltd 水溶性薬物を含有する徐放性製剤
SK286600B6 (sk) * 1999-08-31 2009-02-05 Kissei Pharmaceutical Co., Ltd Glukopyranozyloxypyrazolové deriváty, farmaceutická zmes s ich obsahom a medziprodukty na ich výrobu
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
EP1338603B1 (de) * 2000-11-02 2010-01-20 Ajinomoto Co., Inc. Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
AU2002225356B2 (en) * 2000-12-28 2008-03-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and use thereof in medicines
MXPA05001549A (es) * 2002-08-08 2005-05-05 Kissei Pharmaceutical Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion.
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CA2500873C (en) * 2002-10-04 2012-01-17 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
JP4285338B2 (ja) * 2004-06-14 2009-06-24 トヨタ自動車株式会社 スターリングエンジン

Also Published As

Publication number Publication date
ES2345250T3 (es) 2010-09-20
IL166748A0 (en) 2006-01-15
MXPA05001549A (es) 2005-05-05
US7655632B2 (en) 2010-02-02
BRPI0313290B1 (pt) 2016-12-06
KR100985502B1 (ko) 2010-10-05
RU2005106259A (ru) 2005-08-27
CA2494179A1 (en) 2004-02-19
AU2003254847B2 (en) 2009-06-04
EP1544208B1 (de) 2010-05-26
KR20050059067A (ko) 2005-06-17
US20060166899A1 (en) 2006-07-27
PL213095B1 (pl) 2013-01-31
PL375473A1 (en) 2005-11-28
US7375087B2 (en) 2008-05-20
WO2004014932A1 (ja) 2004-02-19
CA2494179C (en) 2012-04-24
NO20051209L (no) 2005-04-15
TWI341843B (de) 2011-05-11
NZ538117A (en) 2007-01-26
NO330456B1 (no) 2011-04-18
DE60332743D1 (de) 2010-07-08
RU2356906C2 (ru) 2009-05-27
JPWO2004014932A1 (ja) 2005-12-02
JP4540475B2 (ja) 2010-09-08
EP1544208A4 (de) 2007-05-02
US20080312153A1 (en) 2008-12-18
AU2003254847A1 (en) 2004-02-25
BR0313290A (pt) 2005-07-05
HK1082743A1 (en) 2006-06-16
TW200413401A (en) 2004-08-01
EP1544208A1 (de) 2005-06-22

Similar Documents

Publication Publication Date Title
ATE469161T1 (de) Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
ATE264337T1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
ATE312114T1 (de) Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate
WO2002044192A1 (fr) Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
WO2003011880A1 (fr) Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
NZ545692A (en) PPAR-activating compound and pharmaceutical composition containing same
MXPA03002779A (es) Derivados de glucopiranosiloxibencilbenceno y composiciones medicinales conteniendo los mismos.
TW200745070A (en) Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and their use
EP1400529A4 (de) Glucopyranosyloxypyrazol derivat, diese enthaltende medizinische zusammensetzung, dessen medizinische verwendung und zwischenprodukt zu dessen herstellung
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
NO20064412L (no) Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
EP1637539A4 (de) Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
HK1061674A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
IL169577A0 (en) Oligosaccharide derivatives and pharmaceutical compostions containing the same
TW200511990A (en) Novel medical uses of 4, 5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties